HBsAg-TBK1 Interaction: A New Mechanism of HBV Immune Evasion and Autophagy Induction

Study Background and Research Question

Chronic hepatitis B virus (HBV) infection remains a major global health challenge, affecting an estimated 350 million people worldwide and contributing significantly to liver cancer incidence. The HBV surface antigen (HBsAg), a structural protein essential for viral assembly and host cell entry, has long been implicated in immune evasion and persistent infection. However, the mechanistic underpinnings of how HBsAg disrupts host innate immunity, particularly the type I interferon (IFN) response, and its relationship to autophagy pathways in hepatocytes, have remained elusive. The recent study by Luo et al. (Cell Death and Disease, 2025) addresses these knowledge gaps by dissecting the molecular interplay between HBsAg, TANK-binding kinase 1 (TBK1), and the regulation of both interferon signaling and autophagy.

Key Innovation from the Reference Study

The central innovation of this study lies in the identification of a novel mechanism by which HBsAg hijacks TBK1 activity to evade innate immunity and promote early, incomplete autophagy. Specifically, the authors demonstrate that HBsAg directly interacts with the kinase domain of TBK1, enhancing its dimerization and phosphorylation, yet disrupting its association with interferon regulatory factor 3 (IRF3). This bifurcated signaling outcome leads to a suppression of type I interferon induction and a simultaneous upregulation of autophagosome formation, two processes with profound implications for HBV persistence and host-pathogen dynamics (Luo et al., 2025).

Methods and Experimental Design Insights

The study employs a combination of in vitro cell culture models, ex vivo assays, and in vivo analyses using HBsAg transgenic mice and patient liver tissues. Key methodological advances include:

• Protein-protein interaction assays to map the binding of HBsAg to the TBK1 kinase domain and its impact on TBK1-IRF3 complex formation.
• Phosphorylation status assessments of TBK1, IRF3, and sequestosome-1 (p62) to dissect pathway activation and autophagy induction.
• Use of the small molecule TBK1 inhibitor BX795 to functionally dissect the role of TBK1 dimerization and downstream signaling in both autophagy and interferon suppression.
• Reporter assays and chromatin immunoprecipitation to investigate transcriptional regulation of autophagy-related genes, particularly the SNAP29 promoter.
• Validation of findings in liver tissues from HBsAg transgenic mice and chronic HBV patients, confirming translational relevance.

Protocol Parameters

• BX795 treatment: Applied at concentrations optimized for TBK1 inhibition (typically 1–2 μM in cell culture), as supported by prior kinase assay data and consistent with the product information for BX795.
• HBsAg overexpression: Plasmid-driven or recombinant protein delivery, with experimental time courses spanning 24–48 hours for optimal pathway activation and readout.
• Autophagy flux assessment: LC3 and p62 immunoblotting, with lysosomal inhibitors used to distinguish autophagosome formation from degradation block.
• Reporter gene assays: IFNβ and SNAP29 promoter activity measured following HBsAg and/or BX795 treatment to quantify transcriptional effects.
• In vivo validation: Use of HBsAg transgenic mice, with tissue collection at defined timepoints post-infection or transgene activation.

Core Findings and Why They Matter

The study provides several mechanistic insights:

• HBsAg boosts TBK1 phosphorylation and promotes its dimerization, a key activation step for this kinase.
• This activation paradoxically disrupts TBK1’s functional interaction with IRF3, leading to reduced IRF3 phosphorylation and impaired type I IFN production.
• Concurrently, active TBK1 phosphorylates p62, driving autophagosome accumulation, but HBsAg inhibits autophagosome–lysosome fusion by repressing SNAP29 expression, resulting in incomplete autophagy that favors viral replication.
• In both HBsAg transgenic mouse livers and chronic HBV patient samples, the authors observe suppressed IFNβ signaling and autophagosome accumulation, validating the physiological relevance of their model (Luo et al., 2025).

This dual modulation of innate immune signaling and autophagy by HBsAg constitutes a sophisticated viral strategy for immune evasion and persistence. The identification of TBK1 as a central node manipulated by HBV offers a potential target for therapeutic intervention, particularly using small molecule kinase inhibitors that disrupt these specific signaling events.

Comparison with Existing Internal Articles

Several internal resources provide context for the broader utility of TBK1 and PDK1 inhibitors in immunology and cancer research. For example, BX795: Dissecting PDK1 Inhibition and Immune Modulation explores BX795’s dual role as a PDK1 and TBK1 inhibitor, highlighting its value in studies of the PI3K/Akt/mTOR signaling pathway and innate immune modulation. Likewise, BX795: Mechanistic Insights and Emerging Roles in Cancer discusses quantitative and mechanistic aspects of BX795 in cancer cell growth inhibition and immune signaling. The present reference study extends these discussions by demonstrating, in a viral infection context, how manipulation of TBK1 can simultaneously suppress interferon regulatory factor 3 activation and modulate autophagy, reinforcing the multipurpose utility of ATP-competitive kinase inhibitors such as BX795 in dissection of complex signaling networks.

Limitations and Transferability

While the study offers compelling molecular insights, several limitations should be acknowledged:

• Most mechanistic findings are derived from overexpression and pharmacological inhibition in immortalized cell lines, which may not fully recapitulate the complexity of chronic HBV infection in human liver tissue.
• Although in vivo validation was performed in HBsAg transgenic mice and limited patient samples, broader clinical correlation is needed to generalize these findings.
• The focus on TBK1 does not exclude possible contributions from other kinases or viral proteins in the modulation of autophagy and interferon responses.

Nonetheless, the direct demonstration of HBsAg-TBK1 interaction and the resulting functional outcomes provide a robust framework for further exploration and therapeutic targeting, especially in studies aiming to modulate innate immune responses or autophagy in the context of persistent viral infections.

Why this cross-domain matters, maturity, and limitations

The crosstalk between immune signaling and autophagy is increasingly recognized in both virology and cancer biology. The mechanisms uncovered here have implications beyond HBV, potentially informing studies of other persistent viral pathogens and tumor-immune escape. However, translation to clinical intervention will require careful validation in primary tissues and disease models and consideration of context-specific regulatory networks.

Research Support Resources

For researchers aiming to replicate or extend these findings, BX795 (SKU A8222) is a validated small molecule inhibitor of TBK1, PDK1, and IKKε, suitable for kinase and cell-based assays investigating PI3K/Akt/mTOR signaling, innate immune modulation, and the inhibition of interferon regulatory factor 3. According to the product information, BX795 is effective at nanomolar concentrations for kinase inhibition and can be used to dissect signaling events in cancer, immunology, and antiviral research workflows. APExBIO supplies BX795 with detailed handling guidance for experimental reproducibility.